Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci

被引:94
作者
Rand, KH [1 ]
Houck, H [1 ]
机构
[1] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL 32610 USA
关键词
antibiotic synergy; Enterococcus; VRE;
D O I
10.1093/jac/dkh104
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
We used a novel screening method to look for synergy between daptomycin and 18 other antibiotics against 19 strains of high-level vancomycin-resistant enterococci (VRE) (vancomycin MIC greater than or equal to 256 mg/L). In this approach, daptomycin was incorporated into Ca2+-supplemented Mueller-Hinton agar at subinhibitory concentrations, and synergy was screened by comparing test antibiotic Etest MICs on agar with and without daptomycin. A striking reduction in the rifampicin MIC was seen in 11/15 (73.3%) VRE that were resistant to rifampicin, from greater than or equal to12 mg/L to a mean +/- s.d. of 0.22 +/- 0.21 mg/L at daptomycin 0.25 x MIC and 0.85 +/- 0.90 mg/L at daptomycin 0.125 x MIC. Synergy was also observed for 13/19 (68%) isolates with ampicillin (MIC greater than or equal to 128 mg/L). There was no significant synergy between daptomycin and any other antibiotic by this screening method. If confirmed by further studies, daptomycin with either rifampicin or ampicillin may be useful in the management of infections caused by VRE.
引用
收藏
页码:530 / 532
页数:3
相关论文
共 10 条
[1]  
[Anonymous], 2003, NCCLS Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, V6th
[2]   BACTERICIDAL ACTIVITY OF VANCOMYCIN, DAPTOMYCIN, AMPICILLIN AND AMINOGLYCOSIDES AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCUS-FAECIUM [J].
BINGEN, E ;
LAMBERTZECHOVSKY, N ;
LECLERCQ, R ;
DOIT, C ;
MARIANIKURKDJIAN, P .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 (05) :619-626
[3]  
ELIOPOULOS GM, 1995, ANTIBIOTICS LAB MED, P330
[4]   In-vitro activity and killing effect of polycationic peptides on methicillin-resistant Staphylococcus aureus and interactions with clinically used antibiotics [J].
Giacometti, A ;
Cirioni, O ;
Barchiesi, F ;
Scalise, G .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 38 (02) :115-118
[5]   ANTIMICROBIAL ACTIVITY AND SPECTRUM OF LY146032, A LIPOPEPTIDE ANTIBIOTIC, INCLUDING SUSCEPTIBILITY TESTING RECOMMENDATIONS [J].
JONES, RN ;
BARRY, AL .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (04) :625-629
[6]   Multidrug-resistant bacteria: overcoming antibiotic permeability barriers of Gram-negative bacteria [J].
Savage, PB .
ANNALS OF MEDICINE, 2001, 33 (03) :167-171
[7]   Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus [J].
Silverman, JA ;
Perlmutter, NG ;
Shapiro, HM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (08) :2538-2544
[8]   Development of daptomycin for Gram-positive infections [J].
Tally, FP ;
DeBruin, MF .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (04) :523-526
[9]  
Thorne Grace M., 2002, Clinical Microbiology Newsletter, V24, P33, DOI 10.1016/S0196-4399(02)80007-1
[10]   Group of peptides that act synergistically with hydrophobic antibiotics against gram-negative enteric bacteria [J].
Vaara, M ;
Porro, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1801-1805